CLINICAL TRIALS PROFILE FOR TOLVAPTAN
✉ Email this page to a colleague
All Clinical Trials for TOLVAPTAN
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00043758 ↗ | Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2 | 2002-07-01 | The purpose of this study is to study the effects of tolvaptan on the size and function of the left heart chamber (ventricle) in patients with congestive heart failure (CHF) |
NCT00043771 ↗ | Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2 | 2002-05-01 | Patients with congestive heart failure will be assessed for safety and clinical effects of Tolvaptan 30 mg every day versus 15 mg twice a day over a period of 7 days. |
NCT00071331 ↗ | EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | 2003-09-01 | The purpose of this study is to compare the effectiveness of tolvaptan or placebo in adults with worsening congestive heart failure (CHF). |
NCT00072683 ↗ | "SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia | Completed | Otsuka Pharmaceutical Co., Ltd. | Phase 3 | 2003-04-01 | This study's purpose is to determine whether tolvaptan can safely and effectively return the body's balance of sodium and water toward normal, and to characterize and quantify the potential clinical benefits of this treatment. |
NCT00072683 ↗ | "SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | 2003-04-01 | This study's purpose is to determine whether tolvaptan can safely and effectively return the body's balance of sodium and water toward normal, and to characterize and quantify the potential clinical benefits of this treatment. |
NCT00132886 ↗ | Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2 | 2004-12-01 | This study will look at how a single dose of study medication (tolvaptan) versus an inactive sugar pill (placebo) effect pressures in the heart in patients with congestive heart failure. Higher than normal pressures can be related to symptoms of heart failure (shortness of breath, fatigue, etc.). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TOLVAPTAN
Condition Name
Clinical Trial Locations for TOLVAPTAN
Trials by Country
Clinical Trial Progress for TOLVAPTAN
Clinical Trial Phase
Clinical Trial Sponsors for TOLVAPTAN
Sponsor Name